Clinical Trial of Autologous Intravitreal Bone-marrow CD34+ Stem Cells for Retinopathy
Status:
Enrolling by invitation
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This pilot study is to determine whether it would be safe and feasible to inject CD34+ stem
cells from bone marrow into the eye as treatment for patients who are irreversibly blind from
various retinal conditions.